Crinetics to Highlight Broad Pipeline at ENDO 2023

Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.

Two presentations will provide additional clinical evidence and patient-reported data for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for the treatment of acromegaly. An upcoming oral presentation will review previously reported two-year data from the company’s ACROBAT Advance open-label extension study of paltusotine in acromegaly. The presentation will be delivered by Monica R. Gadelha, M.D., Ph.D., professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program. In addition to the maintenance of IGF-1 levels in Advance study participants, Dr. Gahelha will present an analysis of symptom control and other patient-reported outcomes as assessed using the Acromegaly Symptom Diary.

In addition, Crinetics will highlight the results of in vivo studies from preclinical programs developing: (1) a parathyroid hormone receptor type 1 (PTH1R) antagonist for the treatment of primary hyperparathyroidism; and (2) a thyroid-stimulating hormone receptor (TSHR) antagonist for the treatment of Graves’ disease, an autoimmune disorder that can cause hyperthyroidism and the associated thyroid eye disease (orbitopathy).

Additional details on the presentations are shown below:

In addition, on June 15, 2023, the Endocrine Society’s president, Ursula B. Kaiser, M.D. will present R. Scott Struthers, Ph.D., founder and CEO of Crinetics, with the Society’s John D. Baxter Prize for Entrepreneurship for Dr. Struthers’ contributions to drug discovery and development in endocrine diseases. During the award session, Dr. Struthers will present a lecture titled, “Adventures Discovering Nonpeptide Oral Drugs Acting at Peptide Hormone Receptors.” The Baxter Prize was established in memory of Endocrine Society Past President John D. Baxter, M.D., a world-renowned scientist best known for being the first to clone the human growth hormone gene.

Commenting on the award, Dr. Struthers explained, “John Baxter, with one foot in his academic role and another in founding multiple companies, was an icon for the key role that entrepreneurship can play in advancing the field of endocrinology. At Crinetics, we share Dr. Baxter’s vision of harnessing the entrepreneurial spirit of world-class scientists and physicians to repeatedly discover, develop and deliver novel therapies for endocrine disorders with high unmet medical need. I would like to thank the Endocrine Society for awarding this prize, which is a testament to all of the groundbreaking work being done by the Crinetics team.”

The posters and oral presentations will be made available on the Crinetics website in accordance with the ENDO embargo policy. For attendees of ENDO 2023, Crinetics staff will be available to address questions and discuss pipeline programs at the company booth (#1623).

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04894, an investigational, oral ACTH antagonist in development for the treatment of Cushing’s disease and congenital adrenal hyperplasia and for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist in development for congenital hyperinsulinism. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans for the clinical development of paltusotine, CRN04777 and CRN04894, including the therapeutic potential and clinical benefits thereof. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, topline data that we report may change following a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; we may not be able to obtain, maintain and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic and other geopolitical events may disrupt Crinetics’ business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; unexpected adverse side effects or inadequate efficacy of the company’s product candidates that may limit their development, regulatory approval and/or commercialization; the company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Crinetics’ clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics’ drug candidates may not advance in development or be approved for marketing; Crinetics may use its capital resources sooner than expected; any future impacts to our business resulting from geopolitical developments outside our control; and the other risks and uncertainties described in the company’s periodic filings with the SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic reports, including its annual report on Form 10-K for the year ended December 31, 2022. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contacts:
Chas Schultz
VP, IR & Corporate Communications
cschultz@crinetics.com
(858) 450-6464

Investors / Media:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957